Baird Financial Group
NBIX icon

Baird Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Baird Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.72M Buy
39,868
+1,279
+3% +$190K 0.01% 708
2026
Q1 		$5.08M Sell
38,589
-3,616
-9% -$480K 0.01% 734
2025
Q4 		$5.99M Sell
42,205
-4,756
-10% -$689K 0.01% 687
2025
Q3 		$6.59M Sell
46,961
-6,433
-12% -$872K 0.01% 655
2025
Q2 		$6.71M Sell
53,394
-4,426
-8% -$508K 0.01% 625
2025
Q1 		$6.39M Buy
57,820
+3,103
+6% +$393K 0.01% 603
2024
Q4 		$7.47M Buy
54,717
+24,657
+82% +$3.05M 0.01% 574
2024
Q3 		$3.46M Sell
30,060
-38,906
-56% -$5.33M 0.01% 802
2024
Q2 		$9.49M Buy
68,966
+36,799
+114% +$5.05M 0.02% 496
2024
Q1 		$4.44M Buy
32,167
+6,582
+26% +$899K 0.01% 699
2023
Q4 		$3.37M Sell
25,585
-837
-3% -$96.3K 0.01% 780
2023
Q3 		$2.97M Buy
26,422
+178
+0.7% +$18.7K 0.01% 788
2023
Q2 		$2.47M Buy
26,244
+13,710
+109% +$1.34M 0.01% 844
2023
Q1 		$1.27M Sell
12,534
-4,938
-28% -$514K ﹤0.01% 1029
2022
Q4 		$2.09M Buy
+17,472
New +$2.05M 0.01% 856
2022
Q1 		– Sell
-3,460
Closed -$295K – 1892
2021
Q4 		$295K Hold
3,460
– – ﹤0.01% 1681
2021
Q3 		$332K Hold
3,460
– – ﹤0.01% 1631
2021
Q2 		$337K Sell
3,460
-1,013
-23% -$97.1K ﹤0.01% 1545
2021
Q1 		$435K Buy
+4,473
New +$469K ﹤0.01% 1392

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Baird Financial Group's NBIX Position: Q2 2026 in Review

Baird Financial Group increased its Neurocrine Biosciences (NBIX) stake by 3.3% in Q2 2026, buying an estimated $190K and bringing the position to 39,868 shares worth $6.72M. The position accounts for 0.01% of the portfolio, ranked #708.

Baird Financial Group first reported a position in NBIX in Q1 2021 and has held it in 19 quarters since. The position peaked at $9.49M in Q2 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Baird Financial Group held 39,868 shares of Neurocrine Biosciences worth $6.72M as of Q2 2026.
  • Baird Financial Group bought 1,279 Neurocrine Biosciences shares in Q2 2026, an estimated $190K.
  • Neurocrine Biosciences made up 0.01% of Baird Financial Group's portfolio in Q2 2026, its #708 holding.
  • Baird Financial Group first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 19 quarters since.
  • Baird Financial Group's Neurocrine Biosciences position peaked at $9.49M in Q2 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.